Figure 3: Bortezomib inhibition of myeloma cell proliferation in r-Bone culture
The r-Bone assay is a potential platform for studying multiple hematologic malignancies in vitro as well as the investigation of solid tumor metastasis, like breast and prostate carcinomas to the bone matrix.
zPREDICTA has provided customized tumor-specific 3D cell culture models since 2014 and has been actively developing numerous organ-specific matrices to broaden the preclinical tumor offerings since we've been working together.
Reconstructed mouse breast (r-mBreast) and human breast (r-Breast), lung (r-Lung), and prostate (r-Prostate), are currently being characterized and developed. These models will represent new early opportunities to screen test agents in a platform that will more closely mimic in vivo tissue microenvironments without investing in animal studies upfront. The potential to screen targeted chemical libraries in a high throughput 3D assay should be considered in early discovery efforts.
For more information on how these 3D model assays can be applied to your preclinical oncology and immuno-oncology research, contact the scientists at Labcorp Preclinical Oncology.